Literature DB >> 9457428

Gene therapy for infectious diseases.

B A Bunnell1, R A Morgan.   

Abstract

Gene therapy is being investigated as an alternative treatment for a wide range of infectious diseases that are not amenable to standard clinical management. Approaches to gene therapy for infectious diseases can be divided into three broad categories: (i) gene therapies based on nucleic acid moieties, including antisense DNA or RNA, RNA decoys, and catalytic RNA moieties (ribozymes); (ii) protein approaches such as transdominant negative proteins and single-chain antibodies; and (iii) immunotherapeutic approaches involving genetic vaccines or pathogen-specific lymphocytes. It is further possible that combinations of the aforementioned approaches will be used simultaneously to inhibit multiple stages of the life cycle of the infectious agent.

Entities:  

Mesh:

Year:  1998        PMID: 9457428      PMCID: PMC121375          DOI: 10.1128/CMR.11.1.42

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  162 in total

1.  HIV infection is blocked in vitro by recombinant soluble CD4.

Authors:  R A Fisher; J M Bertonis; W Meier; V A Johnson; D S Costopoulos; T Liu; R Tizard; B D Walker; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

2.  A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.

Authors:  R E Hussey; N E Richardson; M Kowalski; N R Brown; H C Chang; R F Siliciano; T Dorfman; B Walker; J Sodroski; E L Reinherz
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

Review 3.  Functional inactivation of genes by dominant negative mutations.

Authors:  I Herskowitz
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

4.  Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines.

Authors:  C Steele; L M Cowsert; E J Shillitoe
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

5.  Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes.

Authors:  S Chada; C E DeJesus; K Townsend; W T Lee; L Laube; D J Jolly; S M Chang; J F Warner
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

6.  Induction of anti-HIV-1 immune responses by retroviral vectors.

Authors:  D J Jolly; J F Warner
Journal:  Biotechnol Ther       Date:  1991

7.  A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1.

Authors:  M Yu; J Ojwang; O Yamada; A Hampel; J Rapapport; D Looney; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Potent inhibition of Epstein-Barr virus by phosphorothioate oligodeoxynucleotides without sequence specification.

Authors:  G Q Yao; S Grill; W Egan; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

9.  Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody.

Authors:  W A Marasco; W A Haseltine; S Y Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

10.  Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes.

Authors:  I Bahner; C Zhou; X J Yu; Q L Hao; J C Guatelli; D B Kohn
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more
  13 in total

1.  Therapeutic effect of a Gag-nuclease fusion protein against retroviral infection in vivo.

Authors:  G Schumann; M Hermankova; K Cannon; J L Mankowski; J D Boeke
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Protective immunity induced by a DNA vaccine-encoding Toxoplasma gondii microneme protein 11 against acute toxoplasmosis in BALB/c mice.

Authors:  Qing Tao; Rui Fang; Weichao Zhang; Yifan Wang; Jianxi Cheng; Yalin Li; Kun Fang; Muhammad Kasib Khan; Min Hu; Yanqin Zhou; Junlong Zhao
Journal:  Parasitol Res       Date:  2013-06-10       Impact factor: 2.289

3.  Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene.

Authors:  H V Nielsen; S L Lauemøller; L Christiansen; S Buus; A Fomsgaard; E Petersen
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

4.  Evaluation of the immune response induced by multiantigenic DNA vaccine encoding SAG1 and ROP2 of Toxoplasma gondii and the adjuvant properties of murine interleukin-12 plasmid in BALB/c mice.

Authors:  Jie Zhang; Shenyi He; Hua Jiang; Tingting Yang; Hua Cong; Huaiyu Zhou; Jiaqin Zhang; Qinmin Gu; Ying Li; Qunli Zhao
Journal:  Parasitol Res       Date:  2007-01-31       Impact factor: 2.289

5.  Protective immunity induced by Toxoplasma gondii rhoptry protein 16 against toxoplasmosis in mice.

Authors:  Zi-Guo Yuan; Xiu-Xiang Zhang; Xian-Hui He; Eskild Petersen; Dong-Hui Zhou; Yong He; Rui-Qing Lin; Xiu-Zhen Li; Xu-Li Chen; Xiao-Ru Shi; Xiu-Ling Zhong; Bing Zhang; Xing-Quan Zhu
Journal:  Clin Vaccine Immunol       Date:  2010-11-24

6.  Evaluation of the adjuvant effect of pidotimod on the immune protection induced by UV-attenuated Toxoplasma gondii in mouse models.

Authors:  Ying Zhao; Bo Huang; Shiguang Huang; Huanqin Zheng; Yun-quan Li; Zhao-rong Lun; Jilong Shen; Yong Wang; Lloyd H Kasper; Fangli Lu
Journal:  Parasitol Res       Date:  2013-06-20       Impact factor: 2.289

7.  Presence of a Human Diarrheagenic Escherichia coli Clone in Captivity Kept Psittacidaes.

Authors:  Guilherme A Marietto-Gonçalves; Silvia M de Almeida; Josias Rodrigues
Journal:  Open Microbiol J       Date:  2011-07-20

Review 8.  Molecular strategies to inhibit HIV-1 replication.

Authors:  Morten Hjuler Nielsen; Finn Skou Pedersen; Jørgen Kjems
Journal:  Retrovirology       Date:  2005-02-16       Impact factor: 4.602

9.  Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL.

Authors:  Yuichiro Habu; Naoko Miyano-Kurosaki; Michiko Kitano; Yumihiko Endo; Masakazu Yukita; Shigeru Ohira; Hiroaki Takaku; Masayuki Nashimoto; Hiroshi Takaku
Journal:  Nucleic Acids Res       Date:  2005-01-12       Impact factor: 16.971

10.  Characterization of polyion complex micelles designed to address the challenges of oligonucleotide delivery.

Authors:  Marie-Hélène Dufresne; Mahmoud Elsabahy; Jean-Christophe Leroux
Journal:  Pharm Res       Date:  2008-05-02       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.